Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVSNASDAQ:CNTXNASDAQ:MENASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$3.26+7.0%$1.70$1.11▼$17.88$63.62M1.62734,845 shs420,948 shsCNTXContext Therapeutics$0.67+20.6%$0.75$0.49▼$2.75$59.65M1.86292,040 shs252,110 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.36 million shs29.28 million shsRNXTRenovoRx$1.38-1.8%$1.05$0.75▼$1.69$50.29M1.3294,416 shs64,398 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio-5.73%+26.88%+110.73%+75.50%-54.92%CNTXContext Therapeutics-4.12%-10.63%-30.88%-31.17%-69.01%ME23andMe0.00%0.00%0.00%-66.58%-94.37%RNXTRenovoRx+0.72%+3.70%+35.92%+46.29%+29.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio2.0274 of 5 stars3.51.00.00.02.61.70.6CNTXContext Therapeutics1.7144 of 5 stars3.61.00.00.01.60.01.3ME23andMeN/AN/AN/AN/AN/AN/AN/AN/ARNXTRenovoRx1.562 of 5 stars3.53.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 3.00Buy$34.75964.97% UpsideCNTXContext Therapeutics 3.20Buy$6.00802.26% UpsideME23andMe 1.00SellN/AN/ARNXTRenovoRx 3.00Buy$7.25427.27% UpsideCurrent Analyst Ratings BreakdownLatest ME, CNTX, RNXT, and ANVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $11.505/19/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.005/8/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/29/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/29/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/28/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.004/21/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/9/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/4/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/27/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/ACNTXContext TherapeuticsN/AN/AN/AN/A$0.74 per shareN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21RNXTRenovoRx$240K209.53N/AN/A($0.28) per share-4.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$2.16N/AN/AN/AN/AN/A-311.00%8/13/2025 (Estimated)CNTXContext Therapeutics-$23.96M-$0.31N/AN/AN/AN/A-58.76%-55.80%8/6/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ARNXTRenovoRx-$10.23M-$0.40N/AN/AN/AN/A-205.96%-110.01%8/12/2025 (Estimated)Latest ME, CNTX, RNXT, and ANVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.23 million$0.20 million5/14/2025Q1 2025CNTXContext Therapeutics-$0.05-$0.05N/A-$0.05N/AN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A3/31/2025Q4 2024RNXTRenovoRx-$0.12-$0.13-$0.01-$0.12$0.17 million$0.04 million3/21/2025Q4 2024ANVSAnnovis Bio-$0.38-$0.43-$0.05-$0.43N/AN/A3/20/2025Q4 2024CNTXContext Therapeutics-$0.05-$0.04+$0.01N/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.662.66CNTXContext TherapeuticsN/A36.9136.91ME23andMeN/A1.050.91RNXTRenovoRxN/A5.665.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%CNTXContext Therapeutics14.03%ME23andMe36.10%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%CNTXContext Therapeutics2.80%ME23andMe26.32%RNXTRenovoRx9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million9.64 millionOptionableCNTXContext Therapeutics789.70 million72.72 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableRNXTRenovoRx636.57 million22.30 millionNot OptionableME, CNTX, RNXT, and ANVS HeadlinesRecent News About These CompaniesRenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 ResultsJune 6 at 7:24 AM | finance.yahoo.comRenovoRx (NASDAQ:RNXT) Given New $11.50 Price Target at Ascendiant Capital MarketsJune 5 at 8:23 AM | marketbeat.comAscendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€June 5 at 6:29 AM | fr.investing.comEarnings call transcript: RenovoRx Q1 2025 revenue exceeds expectationsMay 17, 2025 | investing.comRenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comRenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...May 16, 2025 | finance.yahoo.comLe BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisionsMay 15, 2025 | fr.investing.comTranscription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentesMay 15, 2025 | fr.investing.comRenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comRenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comRenovoRx Reports First Quarter 2025 Financial Results and Business HighlightsMay 15, 2025 | businesswire.comEarnings Preview For RenovoRxMay 14, 2025 | benzinga.comRenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21stMay 14, 2025 | finance.yahoo.comU.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy PlatformMay 6, 2025 | finance.yahoo.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRxApril 30, 2025 | zonebourse.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-PacApril 29, 2025 | zonebourse.comJohns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréasApril 29, 2025 | fr.investing.comJohns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical TrialApril 29, 2025 | finance.yahoo.comRenovoRx ramps up production of FDA-cleared RenovoCathApril 18, 2025 | uk.investing.comRamtin Agah Purchases 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) StockApril 18, 2025 | insidertrades.comLe directeur médical de RenovoRx, Agah Ramtin, achète des actions pour 13.500$April 18, 2025 | fr.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuySuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersME, CNTX, RNXT, and ANVS Company DescriptionsAnnovis Bio NYSE:ANVS$3.26 +0.21 (+6.98%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Context Therapeutics NASDAQ:CNTX$0.66 +0.11 (+20.56%) As of 01:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.RenovoRx NASDAQ:RNXT$1.38 -0.03 (-1.79%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
